This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/drug/DB08993/identifier/wikipedia/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB08993/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08993/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://www.drugs.com/international/

Statements

Subject Item
n2:DB08993
rdf:type
n3:Drug
n3:description
Cyclic basic peptide related to viomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
n3:group
approved
owl:sameAs
n11:DB08993
dcterms:title
Enviomycin
adms:identifier
n6:Enviomycin n7:DB08993 n8:D07897
n3:synonym
Enviomycin Enviomicina Tuberactinomycin N Enviomycine Enviomycinum
n3:salt
n3:synthesisReference
U.S. Patent 3,892,732.
foaf:page
n13:enviomycin.html
n3:IUPAC-Name
n4:271B62FD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6303-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6302-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B62FF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6300-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6301-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B62FB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B62F9-363D-11E5-9242-09173F13E4C5 n4:271B62FC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B62FA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6309-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B630A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6304-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6305-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6307-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6306-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6308-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Mycobacterium tuberculosis
n3:casRegistryNumber
33103-22-9
n3:Bioavailability
n4:271B630F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6311-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6312-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B630E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B630D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6310-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B62FE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B630B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B630C-363D-11E5-9242-09173F13E4C5